Advanced search
Publication Cover
OncoTargets and Therapy Volume 8, 2015 - Issue
Submit an article Journal homepage
61
Views
0
CrossRef citations to date
0
Altmetric
Case Report

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report

Eriko Takatori1 Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka, JapanCorrespondence[email protected]
,
Tadahiro Shoji1 Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka, Japan
,
Takayuki Nagasawa1 Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka, Japan
,
Satoshi Takeuchi1 Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka, Japan
,
Akira Hosoyachi2 Department of Obstetrics and Gynecology, Iwate Prefectural Miyako Hospital, Miyako, Japan
&
Toru Sugiyama1 Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka, Japan
Pages 2097-2100 | Published online: 11 Aug 2015

References

  • BurgerRABradyMFBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
  • PerrenTJSwartAMPfistererJICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
  • AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
  • Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
  • CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
  • SimpkinsFBelinsonJLRosePGAvoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screeningGynecol Oncol2007107111812317658587
  • TakanoMKikuchiYKatoMYoshikawaTKitaTBowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvementGan To Kagaku Ryoho2008351119811984 Japanese19011357
  • BurgerRABradyMFBookmanMARisk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyJ Clin Oncol201432121210121724637999
  • RichardsonDLBackesFJHurtJDWhich factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?Gynecol Oncol20101181475120382413
  • TanyiJLMcCannGHagemannARClinical predictors of bevacizumab-associated gastrointestinal perforationGynecol Oncol2011120346446921168199

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.